KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018
The report provides an extensive research and detailed analysis of the present market along with future outlook.
(EMAILWIRE.COM, December 07, 2018 ) This KOL Insight briefing focuses on KOLs views of Pipeline Therapy Data Presented at EULAR 2018.
Questions topics -
- Opinion on abatacept failing to achieve its primary endpoint in its Phase III LN trial
- Views on the Phase III safety data for abatacept in LN
- Expectations regarding abatacept’s future development in lupus
- Opinion on ustekinumab’s ability to achieve partial improvements using SLEDAI-2K Responder Index-50
- Views on ustekinumab’s Phase III trial design
- Views on the absence of safety endpoints in the Phase III ustekinumab trial in SLE
- Perception of etanercept’s efficacy in discoid lupus erythematosus
- Opinion on etanercept’s safety data from the Phase II TARGET-DLE trial
Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2392047
Key Highlights:
- While most KOLs agreed that abatacept’s future in LN is uncertain, half of the KOLs highlighted that the drug has potential in lupus arthritis
- Most KOLs highlighted that SLEDAI-2K Responder Index-50 data supports ustekinumab use in SLE
- While most KOLs flagged that etanercept may exacerbate lupus features, half of the KOLs highlighted that etanercept has potential in lupus.
Scope:
- The insight briefing is based on Sociable Pharma’s analysis of primary research with our Lupus key opinion leaders (KOLs).
In total, we conducted interviews with 10 KOLs -
- 5 Europe-based & 5 N. America-based
- Interviews performed during Aug 2018
KOL data is analyzed to produce -
- Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts
Reasons to buy:
- Combines Qualitative & semi-quantitative insight from key opinion leaders on Pipeline Therapy Data Presented at EULAR 2018
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2392047
Key Players:
• Janssen
• BMS
• Pfizer
• Merck
Key Points from TOC:
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
Get More Information about this Report@ http://www.orbisresearch.com/reports/index/kol-perspectives-perceptions-of-lupus-pipeline-therapy-data-presented-at-eular-2018
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Questions topics -
- Opinion on abatacept failing to achieve its primary endpoint in its Phase III LN trial
- Views on the Phase III safety data for abatacept in LN
- Expectations regarding abatacept’s future development in lupus
- Opinion on ustekinumab’s ability to achieve partial improvements using SLEDAI-2K Responder Index-50
- Views on ustekinumab’s Phase III trial design
- Views on the absence of safety endpoints in the Phase III ustekinumab trial in SLE
- Perception of etanercept’s efficacy in discoid lupus erythematosus
- Opinion on etanercept’s safety data from the Phase II TARGET-DLE trial
Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2392047
Key Highlights:
- While most KOLs agreed that abatacept’s future in LN is uncertain, half of the KOLs highlighted that the drug has potential in lupus arthritis
- Most KOLs highlighted that SLEDAI-2K Responder Index-50 data supports ustekinumab use in SLE
- While most KOLs flagged that etanercept may exacerbate lupus features, half of the KOLs highlighted that etanercept has potential in lupus.
Scope:
- The insight briefing is based on Sociable Pharma’s analysis of primary research with our Lupus key opinion leaders (KOLs).
In total, we conducted interviews with 10 KOLs -
- 5 Europe-based & 5 N. America-based
- Interviews performed during Aug 2018
KOL data is analyzed to produce -
- Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts
Reasons to buy:
- Combines Qualitative & semi-quantitative insight from key opinion leaders on Pipeline Therapy Data Presented at EULAR 2018
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2392047
Key Players:
• Janssen
• BMS
• Pfizer
• Merck
Key Points from TOC:
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
Get More Information about this Report@ http://www.orbisresearch.com/reports/index/kol-perspectives-perceptions-of-lupus-pipeline-therapy-data-presented-at-eular-2018
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results